Address correspondence to Dr Elan D. Louis, Yale School of Medicine, Department of Neurology, LCI 710, 15 York St, PO Box 20818, New Haven, CT 06520-8018, [email protected].
RELATIONSHIP DISCLOSURE: Dr Louis serves on the clinical advisory boards of CADENT Therapeutics and SAGE Therapeutics, Inc and receives publishing royalties from Elsevier for Merritt’s Neurology.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Louis discusses the unlabeled/investigational use of alprazolam, benzodiazepines, carbidopa/levodopa, clonazepam, gabapentin, primidone, and topiramate for the treatment of essential tremor; trihexyphenidyl for the treatment of dystonic tremor; acetazolamide, baclofen, carbamazepine, clonazepam, ethosuximide, and phenytoin for the treatment of orthostatic tremor; pregabalin for the treatment of neuropathic tremor; benzodiazepines for the treatment of parkinsonian resting tremor; and phenobarbital to treat the side effects of acute nausea and unsteadiness that occur as a result of other treatments for tremor.